Skip to main content
SXTC logo

China SXT Pharmaceuticals, Inc. (SXTC) Stock Price & Analysis

China SXT Pharmaceuticals, Inc. (SXTC) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $2.59 (-8.48%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$2.59 −$0.24 (-8.48%)

China SXT Pharmaceuticals, Inc. · SXTC · NASDAQ

China SXT Pharmaceuticals, Inc. focuses on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers a variety of TCMP products under brands like Suxuantang, Hui Chun Tang, and Tong Ren Tang.

Price as of Nov 19, 2026

Key Statistics

19 of 100

MoonshotScore v2 · China SXT Pharmaceuticals (SXTC)

Weak
Business Quality Poor (18)
Financial Safety Strained (26)
Valuation Full (59)
Growth Durability Shrinking (16)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $1M (Q4 FY2026, quarter ended Mar 2026)
  • Altman Z -0.98 · Piotroski F 4
  • ROE -24.8% · ROA -17.9% · current ratio 7.93

Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SXTC (52 recorded, newest six shown)
RecordedScoreBand
18Weak
18Weak
18Weak
18Weak
19Weak
19Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$2.59
Change on the day-8.48%
Shares traded on the day49.0K

Price & events

Other perspectives

Council score for China SXT Pharmaceuticals (SXTC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Neutral
Growth Durability Negative
Momentum Negative

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Weak

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is China SXT Pharmaceuticals (SXTC), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. China SXT Pharmaceuticals, Inc. (SXTC) is listed on NASDAQ. It employs 56 people. In Q4 FY2026 it reported revenue of $1M and net income of $163,718.

2 · Latest results

What do the latest results show for China SXT Pharmaceuticals (SXTC)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of $1M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026$1M$163,718$27.95 (diluted)
Q3 FY2026$255,741$81,858$13.97 (diluted)
Q2 FY2026$626,570-$6M-$823.37 (diluted)
Q1 FY2026-$1M-$81,858—
3 · Financial strengths and risks

What are the financial strengths and risks for China SXT Pharmaceuticals (SXTC)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -0.98 · Piotroski F 4. Trailing ratios: ROE -24.8% · ROA -17.9% · current ratio 7.93.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.98 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-24.8%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does China SXT Pharmaceuticals compare with its peers?

Short answer

China SXT Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.00 Nov 18, 2026$6.67B96 5-pillar Nov 18, 2026
ANI Pharmaceuticals, Inc. (ANIP) Same industry, near in market value$71.47 Nov 18, 2026$1.62B94 5-pillar Nov 18, 2026
Zoetis Inc. (ZTS) Same industry, near in market value$85.57 Nov 18, 2026$34.8B87 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.85 Nov 19, 2026$12.4B77 5-pillar Nov 18, 2026
Haleon plc (HLN) Same industry, near in market value$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.35 Nov 19, 2026$5.89B74 5-pillar Nov 18, 2026
Takeda Pharmaceutical Company Limited (TAK) Same industry, near in market value$21.27 Nov 18, 2026$68.0B73 5-pillar Nov 18, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.45 Nov 19, 2026$2.34B70 5-pillar Nov 18, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B66 5-pillar Nov 18, 2026
Teva Pharmaceutical Industries Limited (TEVA) Same industry, near in market value$38.54 Nov 19, 2026$45.0B57 5-pillar Nov 18, 2026
Regencell Bioscience Holdings Limited (RGC) Same industry, near in market value$4.69 Nov 18, 2026$2.33B47 5-pillar Nov 18, 2026
Viatris Inc. (VTRS) Same industry, near in market value$19.88 Nov 19, 2026$22.8B35 5-pillar Nov 18, 2026
China SXT Pharmaceuticals (SXTC) — this page$2.59—19

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SXTC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SXTC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about China SXT Pharmaceuticals (SXTC)?

Read these with our analysis →

Investor Questions: SXTC Stock

These answers are editorial: 1 of these 9 answers is drawn from the SXTC research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SXTC?

SXTC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is SXTC a good stock to buy?

Stock Expert AI does not rate SXTC buy, sell or hold. China SXT Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SXTC stock price today?

The last price recorded for China SXT Pharmaceuticals, Inc. (SXTC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about SXTC stock?

Analyst coverage of China SXT Pharmaceuticals, Inc. (SXTC) is limited due to its small market capitalization and financial performance. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are difficult to assess given the company's negative profit margin.

What are the key factors to evaluate for SXTC?

China SXT Pharmaceuticals, Inc. (SXTC) holds a MoonshotScore in the low range. The market for TCM products is constantly evolving, with new ingredients and applications being discovered. Not financial advice.

How frequently does SXTC data refresh on this page?

SXTC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SXTC's recent stock price performance?

China SXT Pharmaceuticals, Inc. (SXTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brands in the TCM market. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SXTC overvalued or undervalued right now?

China SXT Pharmaceuticals, Inc. (SXTC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of SXTC?

Fractional-share availability for China SXT Pharmaceuticals, Inc. (SXTC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 11 figures on this page — 8 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.